1. Tirzepatide is cost-effective compared to semaglutide for knee osteoarthritis in obesity.
2. Quality-adjusted life-years (QALYs) increased by nearly one with tirzepatide.
3. Incremental cost-effectiveness ratio (ICER) for tirzepatide is $57,400 per QALY.
4. Roux-en-Y gastric bypass offers better outcomes than GLP-1 RAs.
5. Sensitivity analyses showed 64% cost-effectiveness for tirzepatide.
6. Pain reduction for tirzepatide was 58%, and for semaglutide, 57%.

Source: Annals of Internal Medicine